19:28 , Sep 10, 2018 |  BC Innovations  |  Distillery Techniques

Disease models

TECHNOLOGY: 3-D models Patient-derived oligocortical spheroids could be used to study demyelinating diseases and screen therapies to treat them. The spheroids were generated by culturing human pluripotent stem cells with platelet derived growth factor AA...
01:46 , Aug 17, 2018 |  BC Innovations  |  Targets & Mechanisms

Unsaturated remyelination

Enzymes downstream in cholesterol biosynthesis could provide new ways to stimulate remyelination that avoid the baggage of previously identified multiple sclerosis targets, according to a group at Case Western. The university is spinning out Convelo...
19:35 , Dec 5, 2017 |  BC Innovations  |  Distillery Therapeutics

Autoimmune disease

INDICATION: Multiple sclerosis (MS) Cell culture and mouse studies suggest GD1A could help treat MS. In cerebellar slices from a mouse model of MS, GD1A increased myelination compared with vehicle. In another model of MS,...
08:00 , Mar 10, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Major histocompatibility complex class II (MHCII); glucose-6-phosphatase catalytic 2 (G6PC2; IGRP); proteolipid protein 1 (PLP1); myelin oligodend

Autoimmune disease INDICATION: Diabetes; rheumatoid arthritis (RA); multiple sclerosis (MS) Mouse studies suggest nanoparticles coated with MHCII molecules bound to disease-relevant peptides could help treat Type I diabetes, RA and MS. In a mouse model...
07:00 , Aug 15, 2013 |  BC Innovations  |  Distillery Techniques

Technology: Disease models

Approach Summary Licensing status Publication and contact information Disease models Genetic duplication mouse model for a hypomyelinating disorder Mice with an engineered genomic duplication at the proteolipid protein 1 (Plp1) locus could be useful for...
07:00 , Oct 25, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Leukodystrophy Proteolipid protein 1 (PLP1) Mouse and patient studies suggest human neural stem cells could help treat hypomyelination diseases. In a mouse model of hypomyelination,...
07:00 , Oct 25, 2012 |  BC Innovations  |  Targets & Mechanisms

Myelination from neural stem cells

University of California, San Francisco , Oregon Health & Science University and StemCells Inc. have found that neural stem cell transplants could remyelinate axons and treat myelination disorders including Pelizaeus-Merzbacher disease. 1,2 The biotech is...
07:00 , Oct 8, 2012 |  BioCentury  |  Product Development

Opexa's progression in MS

Two years after Tcelna failed a Phase II trial in relapsing-remitting multiple sclerosis, Opexa Therapeutics Inc. has restarted development of the cell therapy with a new focus on secondary progressive MS. The company is going...
07:00 , Oct 7, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Autoimmune disease

This week in therapeutics Indication Target/marker/ pathway Summary Licensing status Publication and contact information Autoimmune disease Multiple sclerosis (MS) Lymphocyte antigen 75 (LY75; DEC-205); proteolipid protein 1 (PLP1) A study in mice suggests that DEC-205-targeted...